Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMPAGLIFLOZIN Cause Renal impairment? 338 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 338 reports of Renal impairment have been filed in association with EMPAGLIFLOZIN (Jardiance). This represents 0.9% of all adverse event reports for EMPAGLIFLOZIN.

338
Reports of Renal impairment with EMPAGLIFLOZIN
0.9%
of all EMPAGLIFLOZIN reports
19
Deaths
153
Hospitalizations

How Dangerous Is Renal impairment From EMPAGLIFLOZIN?

Of the 338 reports, 19 (5.6%) resulted in death, 153 (45.3%) required hospitalization, and 28 (8.3%) were considered life-threatening.

Is Renal impairment Listed in the Official Label?

Yes, Renal impairment is listed as a known adverse reaction in the official FDA drug label for EMPAGLIFLOZIN.

What Other Side Effects Does EMPAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,644) Fungal infection (1,941) Blood glucose increased (1,797) Euglycaemic diabetic ketoacidosis (1,769) Weight decreased (1,661) Urinary tract infection (1,439) Ketoacidosis (1,411) Dizziness (1,372) Nausea (1,333) Vomiting (1,201)

What Other Drugs Cause Renal impairment?

LENALIDOMIDE (2,161) EMTRICITABINE\TENOFOVIR DISOPROXIL (2,128) TACROLIMUS (2,124) OMEPRAZOLE (2,075) LANSOPRAZOLE (2,063) METHOTREXATE (1,852) ESOMEPRAZOLE (1,811) PANTOPRAZOLE (1,713) SACUBITRIL\VALSARTAN (1,610) CYCLOSPORINE (1,489)

Which EMPAGLIFLOZIN Alternatives Have Lower Renal impairment Risk?

EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\METFORMIN EMPAGLIFLOZIN vs EMSAM EMPAGLIFLOZIN vs EMTRICITABINE

Related Pages

EMPAGLIFLOZIN Full Profile All Renal impairment Reports All Drugs Causing Renal impairment EMPAGLIFLOZIN Demographics